Anal carcinoma therapy: Can we improve on 5-fluorouracil/mitomycin/ radiotherapy?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 1, 2010, Pages 135-144

  Jiang, Yixing ^a   Mackley, Heath ^a   Cheng, Hua ^a   Ajani, Jaffer A ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 FU; Anal cancer; Mitomycin; Radiation

Indexed keywords

CAPECITABINE; CETUXIMAB; CISPLATIN; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN;

ANUS CARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLOSTOMY; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PATIENT SAFETY; PROGNOSIS; RADIATION DOSE; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 76549111362     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0009     Document Type: Article

References (38)

1. Horner MJ, Ries LA, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Available at: http://seercancergov/ csr/1975-2006/. Accessed November 23, 2009.
2. Greenall MJ, Quan SH, Urmacher C, DeCosse JJ. Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet 1985;161:509-517.
3. Beahrs OH, Wilson SM. Carcinoma of the anus. Ann Surg 1976;184:422-428.
4. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984;54:114-125.
5. Hardcastle JD, Bussey HJ. Results of surgical treatment of squamous cell carcinoma of the anal canal and anal margin seen at St. Mark's Hospital 1928-66. Proc R Soc Med 1968;61:629-630.
6. Nigra ND, Seydel HG, Considine B, et al. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983;51:1826-1829.
7. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-1054.
8. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-2049.
9. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539.
10. Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003;39:45-51.
11. John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2:205-211.
12. Konski A, Garcia M Jr, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114-118.
13. Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996;14:3121-3125.
14. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.
15. Matzinger O, Roelofsen F, Mineur L, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009;45:2782-2791.
16. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
17. Olivatto LO, Meton F, Bezerra M, et al. Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4609.
18. Eng C, Chang GJ, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 4116.
19. James R, Cunningham D, Davidson N, et al. Chemoradiation and maintenance chemotherapy for patients with anal carcinoma: a phase II trial of the UK Co-Ordinating Committee for Cancer Research (UKCCCR) Anal Cancer Trial Working Party [abstract]. Proc Am Soc Clin Oncol 2000;19:Abstract 1045.
20. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract LBA4009.
21. Conroy T, Ducreux M, Lemanski C, et al. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): definitive analysis of the intergroup ACCORD 03 trial [abstract]. J Clin Oncol 299;27(Suppl 1):Abstract 4033.
22. Meropol NJ, Niedzwiecki D, Shank B, et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the Cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008;26:3229-3234.
23. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354-356.
24. Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007;69:155-162.
25. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354-361.
26. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007;25:4581-4586.
27. Bilimoria KY, Bentrem DJ, Rock CE, et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009;52:624-631.
28. Schlienger M, Krzisch C, Pene F, et al. Epidermoid carcinoma of the anal canal treatment results and prognostic variables in a series of 242 cases. Int J Radiat Oncol Biol Phys 1989;17:1141-1151.
29. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007;68:794-800.
30. Ajani JA, Wang X, Izzo JG, et al. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci, 2009; in press.
31. Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009;27:1116-1121.
32. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008;51:147-153.
33. Deniaud-Alexandre E, Touboul E, Tiret E, et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003;56:1259-1273.
34. Mawdsley S, Meadows HM, Royston P, et al. Role of molecular markers in the clinical outcome and prediction of response to treatment in squamous anal cancer [abstract]. Proc Am Soc Clin Oncol 2003;22:Abstract 3566.
35. Bonin SR, Pajak TF, Russell AH, et al. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group. Cancer 1999;85:1226-1233.
36. Wong CS, Tsao MS, Sharma V, et al. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1999;45:309-314.
37. Allal AS, Waelchli L, Brundler MA. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003;9:6489-6496.
38. Nilsson PJ, Lenander C, Rubio C, et al. Prognostic significance of cyclin A in epidermoid anal cancer. Oncol Rep 2006;16:443-449.